Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7597)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Aug 7, 2014 (publication date) through Apr 25, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | De Stefano A, Carlomagno C. Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer. World J Gastroenterol 2014; 20(29): 9732-9743 [PMID: 25110411 DOI: 10.3748/wjg.v20.i29.9732] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v20/i29/9732.htm |
| Number | Citing Articles |
| 1 |
Andrew Dean, Aisling Byrne, Mira Marinova, Ingrid Hayden. Clinical Outcomes of Patients with Rare and Heavily Pretreated Solid Tumors Treated according to the Results of Tumor Molecular Profiling. BioMed Research International 2016; 2016: 1 doi: 10.1155/2016/4627214
|
| 2 |
Maxime Guéguinou, Thomas Harnois, David Crottes, Arnaud Uguen, Nadine Deliot, Audrey Gambade, Aurélie Chantôme, Jean Pierre Haelters, Paul Alain Jaffrès, Marie Lise Jourdan, Günther Weber, Olivier Soriani, Philippe Bougnoux, Olivier Mignen, Nicolas Bourmeyster, Bruno Constantin, Thierry Lecomte, Christophe Vandier, Marie Potier-Cartereau. SK3/TRPC1/Orai1 complex regulates SOCE-dependent colon cancer cell migration: a novel opportunity to modulate anti-EGFR mAb action by the alkyl-lipid Ohmline. Oncotarget 2016; 7(24): 36168 doi: 10.18632/oncotarget.8786
|
| 3 |
Ana Bela Sarmento-Ribeiro, Andreas Scorilas, Ana Cristina Gonçalves, Thomas Efferth, Ioannis P. Trougakos. The emergence of drug resistance to targeted cancer therapies: Clinical evidence. Drug Resistance Updates 2019; 47: 100646 doi: 10.1016/j.drup.2019.100646
|
| 4 |
Sarah Wedden, Keith Miller, Ian M. Frayling, Teresa Thomas, Alina Chefani, Karolina Miller, Angela Hamblin, Jenny C. Taylor, Corrado D’Arrigo. Colorectal Cancer Stratification in the Routine Clinical Pathway: A District General Hospital Experience. Applied Immunohistochemistry & Molecular Morphology 2019; 27(6): e54 doi: 10.1097/PAI.0000000000000631
|
| 5 |
Junsheng Deng, Xiaoli Chen, Ting Zhan, Mengge Chen, Xisheng Yan, Xiaodong Huang. CRYAB predicts clinical prognosis and is associated with immunocyte infiltration in colorectal cancer. PeerJ 2021; 9: e12578 doi: 10.7717/peerj.12578
|
| 6 |
Mariamena Arbitrio, Maria Teresa Di Martino, Francesca Scionti, Giuseppe Agapito, Pietro Hiram Guzzi, Mario Cannataro, Pierfrancesco Tassone, Pierosandro Tagliaferri. DMET™ (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine. Oncotarget 2016; 7(33): 54028 doi: 10.18632/oncotarget.9927
|
| 7 |
SHUN-ICHI SUZUKI, SATOSHI MATSUSAKA, MITSUHARU HIRAI, HARUMI SHIBATA, KOICHI TAKAGI, NOBUYUKI MIZUNUMA, KIYOHIKO HATAKE. A novel approach to detect KRAS/BRAF mutation for colon cancer: Highly sensitive simultaneous detection of mutations and simple pre-treatment without DNA extraction. International Journal of Oncology 2015; 47(1): 97 doi: 10.3892/ijo.2015.2978
|
| 8 |
J.H.L. Neumann, A. Jung, T. Kirchner. Molekulare Pathologie des kolorektalen Karzinoms. Der Pathologe 2015; 36(2): 137 doi: 10.1007/s00292-015-0005-3
|
| 9 |
William A. Hammond, Abhisek Swaika, Kabir Mody. Pharmacologic resistance in colorectal cancer: a review. Therapeutic Advances in Medical Oncology 2016; 8(1): 57 doi: 10.1177/1758834015614530
|
| 10 |
Vivien Hichert, Catharina Scholl, Michael Steffens, Tanusree Paul, Christian Schumann, Stefan Rüdiger, Stefan Boeck, Volker Heinemann, Volker Kächele, Thomas Seufferlein, Julia Stingl. Predictive blood plasma biomarkers for EGFR inhibitor-induced skin rash. Oncotarget 2017; 8(21): 35193 doi: 10.18632/oncotarget.17060
|
| 11 |
Cheng-Chin Lee, Ai-Wei Lee, Po-Li Wei, Yi-Shin Liu, Yu-Jia Chang, Chien-Yu Huang. In silico analysis to identify miR-1271-5p/PLCB4 (phospholipase C Beta 4) axis mediated oxaliplatin resistance in metastatic colorectal cancer. Scientific Reports 2023; 13(1) doi: 10.1038/s41598-023-31331-2
|
| 12 |
Anna M. Valentini, Elisabetta Cavalcanti, Marianna Di Maggio, Maria L. Caruso. RAS-expanded Mutations and HER2 Expression in Metastatic Colorectal Cancer: A New Step of Precision Medicine. Applied Immunohistochemistry & Molecular Morphology 2018; 26(8): 539 doi: 10.1097/PAI.0000000000000475
|
| 13 |
P. Reijonen, P. Österlund, H. Isoniemi, J. Arola, A. Nordin. Histologically Verified Biliary Invasion was Associated with Impaired Liver Recurrence-Free Survival in Resected Colorectal Cancer Liver Metastases. Scandinavian Journal of Surgery 2019; 108(3): 201 doi: 10.1177/1457496918812237
|
| 14 |
Nathaniel Edward Bennett Saidu, Marie Bretagne, Audrey Lupo Mansuet, Pierre-Alexandre Just, Karen Leroy, Olivier Cerles, Sandrine Chouzenoux, Carole Nicco, Diane Damotte, Marco Alifano, Bruno Borghese, François Goldwasser, Frédéric Batteux, Jérôme Alexandre. Dimethyl fumarate is highly cytotoxic in KRAS mutated cancer cells but spares non-tumorigenic cells. Oncotarget 2018; 9(10): 9088 doi: 10.18632/oncotarget.24144
|
| 15 |
Serena Bonin. Is it Possible to Predict Benefit from 5FU Adjuvant Therapy in Stage III Colon Cancer Patients?. EBioMedicine 2015; 2(8): 780 doi: 10.1016/j.ebiom.2015.06.011
|
| 16 |
Jens H.L. Neumann, Andreas Jung, Thomas Kirchner. Molekulare Pathologie des kolorektalen Karzinoms. Wiener klinisches Magazin 2015; 18(4): 140 doi: 10.1007/s00740-015-0061-6
|
| 17 |
D. S. Mikhailenko, G. D. Efremov, N. Yu. Safronova, V. V. Strelnikov, B. Ya. Alekseev. Detection of Rare Mutations by Routine Analysis of KRAS, NRAS, and BRAF Oncogenes. Bulletin of Experimental Biology and Medicine 2017; 162(3): 375 doi: 10.1007/s10517-017-3619-z
|
| 18 |
Kiyoko Takane, Kiwamu Akagi, Masaki Fukuyo, Koichi Yagi, Tadatoshi Takayama, Atsushi Kaneda. DNA methylation epigenotype and clinical features of NRAS‐mutation(+) colorectal cancer. Cancer Medicine 2017; 6(5): 1023 doi: 10.1002/cam4.1061
|
| 19 |
Shih‑Chang Chuang, Ching‑Wen Huang, Yi‑Ting Chen, Cheng‑Jen Ma, Hsiang‑Lin Tsai, Tsung‑Kun Chang, Wei‑Chih Su, Wen‑Hung Hsu, Chao‑Hung Kuo, Jaw‑Yuan Wang. Effect of KRAS and NRAS mutations on the prognosis of patients with synchronous metastatic colorectal cancer presenting with liver‑only and lung‑only metastases. Oncology Letters 2020; 20(3): 2119 doi: 10.3892/ol.2020.11795
|
| 20 |
Giorgio Stanta, Stephan Wenzel Jahn, Serena Bonin, Gerald Hoefler. Tumour heterogeneity: principles and practical consequences. Virchows Archiv 2016; 469(4): 371 doi: 10.1007/s00428-016-1987-9
|
| 21 |
Krizelle Mae M. Alcantara, Joshua Reginald P. Malapit, Ryan Timothy D. Yu, Jose Antonio Ma. G. Garrido, John Paul T. Rigor, Arlou Kristina J. Angeles, Eva Maria Cutiongco-de la Paz, Reynaldo L. Garcia. Non-Redundant and Overlapping Oncogenic Readouts of Non-Canonical and Novel Colorectal Cancer KRAS and NRAS Mutants. Cells 2019; 8(12): 1557 doi: 10.3390/cells8121557
|
| 22 |
Youngchul Kim, Daewon Kim, Biwei Cao, Rodrigo Carvajal, Minjung Kim. PDXGEM: patient-derived tumor xenograft-based gene expression model for predicting clinical response to anticancer therapy in cancer patients. BMC Bioinformatics 2020; 21(1) doi: 10.1186/s12859-020-03633-z
|
| 23 |
Marina De Rosa, Daniela Rega, Valeria Costabile, Francesca Duraturo, Antonello Niglio, Paola Izzo, Ugo Pace, Paolo Delrio. The biological complexity of colorectal cancer: insights into biomarkers for early detection and personalized care. Therapeutic Advances in Gastroenterology 2016; 9(6): 861 doi: 10.1177/1756283X16659790
|
| 24 |
T. Yoshino, D.C. Portnoy, R. Obermannová, G. Bodoky, J. Prausová, R. Garcia-Carbonero, T. Ciuleanu, P. García-Alfonso, A.L. Cohn, E. Van Cutsem, K. Yamazaki, S. Lonardi, K. Muro, T.W. Kim, K. Yamaguchi, A. Grothey, J. O’Connor, J. Taieb, S.R. Wijayawardana, R.R. Hozak, F. Nasroulah, J. Tabernero. Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE—a global phase III study. Annals of Oncology 2019; 30(1): 124 doi: 10.1093/annonc/mdy461
|